Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The duration over which antibody responses persist following HPV vaccination is unknown. To estimate the longevity of responses induced by HPV-16 vaccination, two models were fitted to serum anti-HPV-16 levels measured during a 48-month study period. The first was a conventional model of antibody decay and the second was a modified model that accounts for long-lived immune memory. Using the antibody decay model, it was estimated that following administration of a three-dose regimen of HPV-16 vaccine in women aged 16-23 years, anti-HPV-16 levels will remain above those induced naturally by HPV-16 infection for 12 years, and above detectable levels for 32 years in 50% of vaccinees. With the modified model, which fitted the data better (p<0.001), it was estimated that near life-long persistence of anti-HPV-16 following vaccination is expected at titer levels above those associated with reduction of natural HPV-16 infection in 76% of these subjects, and above detectable levels in 99% of these subjects.

Original publication

DOI

10.1016/j.vaccine.2007.02.069

Type

Journal article

Journal

Vaccine

Publication Date

05/2007

Volume

25

Pages

4324 - 4333

Addresses

Imperial College London, London, UK.

Keywords

Humans, Papillomavirus Infections, Vaccines, Virosome, Antibodies, Viral, Follow-Up Studies, Models, Immunological, Time Factors, Adolescent, Adult, Uterine Cervical Neoplasms, Female, Human papillomavirus 16, Papillomavirus Vaccines